...
机译:Neoadjuvant放射治疗与单独的手术单独进行II / III中低直肠癌,或没有高风险因素的预测多中心分层随机试验
Sichuan Univ West China Hosp Dept Gastrointestinal Surg Chengdu Peoples R China;
Kunming Med Univ Affiliated Hosp 3 Colorectal Canc Clin Res Ctr Kunming Yunnan Peoples R China;
Sichuan Univ West China Hosp Dept Pathol Chengdu Peoples R China;
Sichuan Univ West China Hosp Dept Gastrointestinal Surg Chengdu Peoples R China;
Sichuan Univ West China Hosp Dept Abdominal Canc Canc Ctr Chengdu Peoples R China;
Sichuan Univ West China Hosp Dept Gastrointestinal Surg Chengdu Peoples R China;
Third Peoples Hosp Chengdu Dept Gen Surg Chengdu Peoples R China;
Sichuan Univ West China Hosp Dept Radiol Chengdu Peoples R China;
Third Peoples Hosp Chengdu Dept Gen Surg Chengdu Peoples R China;
Sichuan Univ West China Hosp Dept Abdominal Canc Canc Ctr Chengdu Peoples R China;
Sichuan Univ West China Hosp Dept Ultrasound Chengdu Peoples R China;
Sichuan Univ West China Hosp Dept Gastrointestinal Surg Chengdu Peoples R China;
Kunming Med Univ Affiliated Hosp 3 Colorectal Canc Clin Res Ctr Kunming Yunnan Peoples R China;
Sichuan Univ West China Hosp Dept Abdominal Canc Canc Ctr Chengdu Peoples R China;
Sichuan Univ West China Hosp Dept Gastrointestinal Surg Chengdu Peoples R China;
local recurrence; rectal cancer; risk stratification; short-course radiotherapy; total moserectal excision;
机译:高危直肠癌(EXPERT-C)患者的新中心奥沙利铂,卡培他滨和术前放疗伴或不伴西妥昔单抗再行全肠系膜切除术的多中心随机II期临床试验。
机译:围手术期Folfox 4对Folfox 4加上西替昔单抗与高风险阶段II和III结肠癌的直接手术同期多中心随机对照试验(Prodipe 22)
机译:术后Xelox疗法治疗患者高风险阶段II和III阶段直肠癌,无术前化学校长:前瞻性,多中心,开放标签,单臂期II研究
机译:胃癌外科预期多中心试验 - 对质量控制临床研究的贡献
机译:具有阶段I,II或III肺,结肠或直肠癌的退伍军人治疗发起的医院和患者特征
机译:治愈性高危II期和III期直肠癌患者未进行术前放化疗的术后XELOX疗法:一项前瞻性多中心开放标签单臂II期研究
机译:术前长程化放疗加辅助化疗与无辅助化疗的短程放疗同时进行II-III期可切除直肠癌的延迟手术:随机对照试验的5年生存数据
机译:静脉注射羟钴胺素与全血输注的前瞻性随机试验相比,在院前猪模型中未治疗III类失血性休克复苏。